NAD+ vs NMN: what the evidence actually says

NAD+ vs NMN.

This one is not really a matchup between two competing products — it is a molecule and one of its oral precursors, which people end up choosing between anyway because both are sold for the same reason. The question worth asking is not which raises NAD+ more. It is which one the human trial data is actually about, and whether raising NAD+ has been shown to do anything durable. Those two answers point in different directions.

Cellular energy · Molecule vs precursor

	NAD+	NMN
Evidence tier	Early human dataHuman data exists but is small, old, single-group, non-Western, or for a different route than people actually use.	Not graded.NMN is an oral precursor, not one of the injectable compounds this site grades. It is covered descriptively in the NAD+ deep dive.
Regulatory status	Not approved for human use	Sold as a supplement.Not approved as a supplement in some jurisdictions, which creates a legal grey area.
Researched for	A coenzyme central to cellular energy and DNA repair. Its age-related decline anchors much of modern longevity research.	An oral NAD+ precursor, converted to NAD+ by enzymatic steps. Covered on this site descriptively rather than graded — it is not one of the injectables in the field guide.
What people use it for	Higher energy; reduced fatigue; sharper mental clarity and focus; improved mood or motivation, especially with injectable or IV forms.	Taken orally as a daily longevity supplement, for the same energy, cognition and healthy-aging reasons.
Reported figure	1000 mg vial + 8 mL water = 125,000 mcg/mL 50 mg → 0.40 mL · 40 unitsOne reported reference at that reconstitution — not a standard.	Not graded on this site. The deep dive reports 250–500 mg/day oral in published research protocols.
Route	Subcutaneous or intramuscular by convention; clinic use is intravenous, which is a different setting entirely.	Oral, daily.
Calculator entry	Yes — NAD+ calculator	No — it is an oral supplement, so there is nothing to reconstitute.

Scroll the table sideways →

The honest difference

The compound with the human trials is not the one people inject.

The grading here is blunt about it: NAD+ is “a coenzyme rather than a peptide. Most human trial data covers the oral precursors NMN and NR, not injected NAD+. Clinic IV use is widespread but thinly evidenced, and IV doses do not transfer to a subcutaneous syringe.” Every part of that sentence is load-bearing. The trials are about the precursor. The injectable's popularity comes from clinics, not from a literature. And the large numbers people see quoted come from IV sessions, which cannot be read across to a subcutaneous draw.

The precursor side has real, if small, human work — and this site's deep dive covers it. A 12-week trial published in npj Aging in 2022 gave 250 mg a day to healthy men aged 65 and over and found raised blood NAD+ alongside improved gait speed and grip strength. A 2021 paper in Science reported improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes after roughly ten weeks. Both are small and short.

What is consistent across the human literature is that precursors raise NAD+ levels. What is missing is whether that matters over time: some evidence for physical performance, mixed evidence for insulin sensitivity, limited cognitive data, and no long-term healthspan or lifespan data at all. The surrogate marker moves; the outcome is unproven.

So the trials belong to the oral route, while the injectable carries the reputation.

Which questions actually matter

Which route does the human data describe?Most human trial data covers the oral precursors. Injected NAD+ is not what was studied, and clinic IV use is widespread but thinly evidenced.

Can an IV figure be read across to a syringe?It cannot. IV doses do not transfer to a subcutaneous injection — different setting, different delivery, different arithmetic.

Does raising NAD+ prove anything on its own?Levels rise consistently in humans. Whether raising them for years produces a durable benefit has not been shown — that gap is the whole debate.

Is the trial size doing the work the headline implies?The two most-cited human trials ran roughly 10 to 12 weeks in small, specific groups. Promising and preliminary are not the same thing.

Oral convenience versus injection?One is a daily capsule, the other a subcutaneous draw or a clinic appointment. That is a practical trade-off, and it runs opposite to where the evidence sits.

Read each one on its own terms

Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.

A comparison, not a recommendation. Nothing on this page ranks one compound above another or suggests running either. Where a figure appears, it is one reported reference at the reconstitution shown — not a standard, not a clinical dose.

Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.

Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Several of these are prescription medicines in Canada and the US, and several are approved nowhere at all. Consult a qualified healthcare professional before beginning any protocol.

For education only · Not medical adviceSourced clean · Documented in full

NAD+ vs NMN.

NAD+

NMN